Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects.,Journal of Hypertension

当前位置： X-MOL 学术 › J. Hypertens. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects.
Journal of Hypertension ( IF 4.9 ) Pub Date : 2023-12-11 , DOI: 10.1097/hjh.0000000000003633
Edwyn O. Cruz-López ₁ , Dien Ye ₁ , Daniel G. Stolk ₁ , Marian C. Clahsen-van Groningen ₂ , Richard van Veghel ₁ , Ingrid M. Garrelds ₁ , Marko Poglitsch ₃ , Oliver Domenig ₃ , Rahi S. Alipour Symakani _{4,

5,

6} , Daphne Merkus ₄ , Koen Verdonk ₁ , A.H. Jan Danser ₁

Affiliation

Sodium-glucose cotransporter-2 (SGLT2) inhibition exerts cardioprotective and renoprotective effects, often on top of renin-angiotensin system (RAS) blockade. We investigated this in diabetic hypertensive (mREN2)27 rats.

中文翻译：

在实验性糖尿病中，将肾素-血管紧张素系统阻断和钠-葡萄糖协同转运蛋白-2 抑制相结合可产生协同有益作用。

钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制通常在肾素-血管紧张素系统 (RAS) 阻断的基础上发挥心脏保护和肾脏保护作用。我们在糖尿病高血压 (mREN2)27 大鼠中对此进行了研究。

更新日期：2023-12-11

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>